title: [A case of pure-sensory-type Guillain-Barré syndrome with galactocerebroside antibody].
abstract: A 67-year-old man noticed paresthesia in both legs in July 2011. Three days later, he was found on a street where he was unable to stand up. On admission, the deep sensation in both legs was severely disturbed, but their muscle strength remained normal. Cranial nerves and autonomic functions were normal. The deep tendon reflexes were diminished in both legs. Magnetic resonance imaging of the spine was normal. Motor nerve conduction studies revealed normal conduction velocity, amplitude, and F-wave latency. However, sensory nerve conduction studies revealed severe reduction of amplitude in the upper and lower extremities. Cerebrospinal fluid analysis showed normal cell counts but elevated protein levels. Screening for glycolipid antibodies showed a selective increase of galactocerebroside (Gal-C) IgG antibody. We diagnosed him with pure-sensory-type Guillain-Barré syndrome (GBS). We administered intravenous immunoglobulin (IVIG) for 5 days. After IVIG therapy, his gait disturbance improved slightly but the disturbance of deep sensation remained severe and he was transferred to a rehabilitation ward 53 days after admission. To the best of our knowledge, this is the first report of a case of pure-sensory-type GBS with Gal-C antibody alone. This case suggests a close relationship between Gal-C antibody and sensory nerve disturbance.
authors: Department of Internal Medicine, Kohka Public Hospital.
authors: Shuro
authors: S
authors: Kogawa
authors: Atsushi
authors: A
authors: Nakajima
authors: Syuhei
authors: S
authors: Kobashi
authors: Makoto
authors: M
authors: Samukawa
authors: Susumu
authors: S
authors: Kusunoki
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005699:Galactosylceramides / Q000276:immunology*; D020275:Guillain-Barre Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D008297:Male; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D005699:Galactosylceramides; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; C002454:galactocerebroside